Main content

    Esophageal Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at

    Active Trials

    Title: A Phase III Trial Evaluating The Addition Of Trastuzumab To Trimodality Treatment Of Her2-Overexpressing Esophageal Adenocarcinoma
    Description: Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have pathologically confirmed primary adenocarcinoma of the esophagus, distal, or esophagogastric junction
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: about Study RTOG 1010

    • updated June 2015

    Back to top